Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 4327.

https://doi.org/10.1182/blood-2019-123640

Published: 2019

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Blood (2018) 132 (23): 2465–2469.

https://doi.org/10.1182/blood-2018-06-857250

Published: 2018

Includes: Supplemental data

Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2018-99-111823

Published: 2018

Journal Articles

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Priya Sriskandarajah, MBBS, BSc, MRCP, Kevin Boyd, Wen Xu, MD, Irene Moreno Candilejo, MD, Sidra Ellis, Amy Price, Amy L Sherborne, PhD, James Croft, MBBS, BSc, Vallari Shah, MBBS, Joanna Dawes, PhD, Mona Parmar, Alison Turner, Emma Hall, BSc, MSc, PhD, Nina Tunariu, MBBS, MDes, MRCP, FRCR, Juanita S Lopez, MB BChir, MRCP, PhD, Johann S. de Bono, Udai Banerji, MBBS, MD DNB, PhD FRCP, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2018-99-111821

Published: 2018

Journal Articles

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Debbie Sherratt, Sadie Reed, PhD, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2018-99-111835

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 3072.

https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072

Published: 2017

Journal Articles

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Andrew Hall, Katrina Walker, Sidra Ellis, Farzana Begum, David C Johnson, James Croft, BSc, MBBS, MRCP, Jack Kendall, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Lilit Atanesyan, Suvi Savola, Louise Flanagan, Anjan Thakurta, PhD, Mamta Garg, MD, Gordon Cook, MD PhD, Kevin Boyd, Sarah Brown, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1851.

https://doi.org/10.1182/blood.V130.Suppl_1.1851.1851

Published: 2017

Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1767.

https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767

Published: 2017

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Blood (2016) 128 (22): 4412.

https://doi.org/10.1182/blood.V128.22.4412.4412

Published: 2016

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype

Blood (2013) 122 (19): 3298–3307.

https://doi.org/10.1182/blood-2013-03-491316

Published: 2013

Includes: Supplemental data

NARROW

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only